{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T20:10:38Z","timestamp":1769631038319,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.drudis.2022.01.002","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T11:41:33Z","timestamp":1641555693000},"page":"1483-1494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The changing landscape of treatment options in childhood acute lymphoblastic leukaemia"],"prefix":"10.1016","volume":"27","author":[{"given":"Benjamin","family":"Micallef","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Nistic\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinan.B.","family":"Sarac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole W.","family":"Bjerrum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianne","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolette","family":"Sammut Bartolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Serracino-Inglott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Joseph","family":"Borg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.drudis.2022.01.002_b0005","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S1470-2045(13)70010-X","article-title":"Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries","volume":"14","author":"Pritchard-Jones","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.drudis.2022.01.002_b0010","first-page":"83","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.drudis.2022.01.002_b0015","first-page":"212","article-title":"Improving the outcome for children with cancer: development of targeted new agents","volume":"65","author":"Adamson","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.drudis.2022.01.002_b0020","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2017.74.4946","article-title":"Reduced-intensity delayed intensification in standard-risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: results of an international randomized trial (AIEOP-BFM ALL 2000)","volume":"36","author":"Schrappe","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.drudis.2022.01.002_b0025","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/s41375-019-0670-y","article-title":"Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial","volume":"34","author":"Attarbaschi","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.drudis.2022.01.002_b0030","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41375-020-01024-0","article-title":"Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990\u20132015","volume":"35","author":"Reedijk","year":"2021","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.drudis.2022.01.002_b0035","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A history of cancer chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.drudis.2022.01.002_b0040","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/pbc.24598","article-title":"Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria","volume":"60","author":"Rossig","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.drudis.2022.01.002_b0045","first-page":"105","article-title":"Hematopoietic stem cell transplantation","volume":"3","author":"Hatzimichael","year":"2010","journal-title":"Stem Cells Cloning"},{"issue":"6","key":"10.1016\/j.drudis.2022.01.002_b0050","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-05-378943","article-title":"Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?","volume":"120","author":"Pui","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.drudis.2022.01.002_b0055","doi-asserted-by":"crossref","DOI":"10.5041\/RMMJ.10162","article-title":"Hematopoietic stem cell transplantation\u201350 years of evolution and future perspectives","volume":"5","author":"Henig","year":"2014","journal-title":"Rambam Maimonides Med J"},{"issue":"1","key":"10.1016\/j.drudis.2022.01.002_b0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pcl.2014.09.004","article-title":"Biology of childhood acute lymphoblastic leukemia","volume":"62","author":"Bhojwani","year":"2015","journal-title":"Pediatr Clin North Am"},{"issue":"3","key":"10.1016\/j.drudis.2022.01.002_b0065","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.seminhematol.2013.06.007","article-title":"A 50-year journey to cure childhood acute lymphoblastic leukemia","volume":"50","author":"Pui","year":"2013","journal-title":"Semin Hematol"},{"key":"10.1016\/j.drudis.2022.01.002_b0070","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/697675","article-title":"Outcome of adolescents with acute lymphoblastic leukemia treated by pediatrics versus adults protocols","volume":"2014","author":"Ibrahim","year":"2014","journal-title":"Adv Hematol"},{"issue":"3","key":"10.1016\/j.drudis.2022.01.002_b0075","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1\u201345 years with acute lymphoblastic leukemia","volume":"32","author":"Toft","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.drudis.2022.01.002_b0080","first-page":"29","article-title":"Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications","volume":"8","author":"Mohseni","year":"2018","journal-title":"Am J Blood Res"},{"issue":"10","key":"10.1016\/j.drudis.2022.01.002_b0085","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2352-4642(20)30247-9","article-title":"The RACE to accelerate drug development for children with cancer","volume":"4","author":"Pearson","year":"2020","journal-title":"Lancet Child Adolesc Health"},{"issue":"6","key":"10.1016\/j.drudis.2022.01.002_b0090","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/0009922809332680","article-title":"Late effects in long-term survivors after treatment for childhood acute leukemia","volume":"48","author":"Haddy","year":"2009","journal-title":"Clin Pediatr (Phila)"},{"issue":"8","key":"10.1016\/j.drudis.2022.01.002_b0095","first-page":"107","article-title":"Late effects and survivorship issues in patients with neuroblastoma","volume":"5","author":"Friedman","year":"2018","journal-title":"Children (Basel)"},{"issue":"1","key":"10.1016\/j.drudis.2022.01.002_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4274\/tjh.galenos.2018.2018.0150","article-title":"Late effects of therapy in childhood acute lymphoblastic leukemia survivors","volume":"36","author":"K\u0131z\u0131locak","year":"2019","journal-title":"Turk J Haematol"},{"issue":"Suppl. 1","key":"10.1016\/j.drudis.2022.01.002_b0105","first-page":"S73","article-title":"ALL-REZ BFM\u2013the consecutive trials for children with relapsed acute lymphoblastic leukemia","volume":"225","author":"Henze","year":"2013","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.drudis.2022.01.002_b0110","unstructured":"EMA. Download medicine data \u2013 European Public Assessment Reports (EPAR) section. European Medicines Agency. www.ema.europa.eu\/en\/medicines\/download-medicine-data#european-public-assessment-reports-(epar)-section [accessed January 4, 2022]."},{"key":"10.1016\/j.drudis.2022.01.002_b0115","unstructured":"Clinical Trials. EU Clinical Trials Register. www.clinicaltrialsregister.eu\/ctr-search\/search [accessed January 4, 2022]."},{"key":"10.1016\/j.drudis.2022.01.002_b0120","unstructured":"EMA. Download medicine data \u2013 Paediatric Investigation Plans section. European Medicines Agency. www.ema.europa.eu\/en\/medicines\/download-medicine-data#paediatric-investigation-plans-section [accessed January 4, 2022]."},{"key":"10.1016\/j.drudis.2022.01.002_b0125","unstructured":"U.S. National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov [accessed January 4, 2022]."},{"key":"10.1016\/j.drudis.2022.01.002_b0130","unstructured":"CHMP. Assessment Report Oncaspar - EMA\/826135\/2016. European Medicines Agency. https: \/\/www.ema.europa.eu\/en\/documents\/assessment-report\/oncaspar-epar-public-assessment-report_en.pdf [accessed January 4, 2022]."},{"key":"10.1016\/j.drudis.2022.01.002_b0135","unstructured":"NCT01574274 - SC\u2013PEG asparaginase vs. oncaspar in pediatric acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01574274 [accessed January 4, 2022]."},{"key":"10.1016\/j.drudis.2022.01.002_b0140","unstructured":"EudraCT Number: 2009-012584-34 - a multicentre, open, randomized, Phase II\/III study, evaluating efficacy and safety of erythrocytes encapsulating L-Asparaginase (GRASPA\u00ae) versus reference L-asparaginase treatment in combination with standard polychemotherapy in patients with first recurrence of Philadelphia chromosome negative Acute Lymphoblastic Leukemia (ALL Ph-). EU Clinical Trials Register. www.clinicaltrialsregister.eu\/ctr-search\/trial\/2009-012584-34\/BE [accessed January 4, 2022]."},{"key":"10.1016\/j.drudis.2022.01.002_b0145","unstructured":"EudraCT Number: 2016-004451-70 - NOR-GRASPALL 2016: Single arm pharmacokinetic\/pharmacodynamic and safety study of Eryaspase (GRASPA\u00ae) for patients with hypersensitivity to peg-asparginase, diagnosed with PH(-) Acute Lymphoblastic Leukemia, EU Clinical Trials Register website. https: \/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004451-70\/DK [accessed January 4, 2022]."},{"key":"10.1016\/j.drudis.2022.01.002_b0150","unstructured":"CHMP. CHMP assessment report Mercaptopurine Nova Laboratories - EMA\/CHMP\/668488\/2011. European Medicines Agency. www.ema.europa.eu\/en\/documents\/assessment-report\/mercaptopurine-nova-laboratories-epar-public-assessment-report_en.pdf [accessed January 4, 2022]."},{"key":"10.1016\/j.drudis.2022.01.002_b0155","unstructured":"CHMP. Assessment report Jylamvo - EMA\/78284\/2017. European Medicines Agency. www.ema.europa.eu\/en\/documents\/assessment-report\/jylamvo-epar-public-assessment-report_en.pdf [accessed January 4, 2022]."},{"key":"10.1016\/j.drudis.2022.01.002_b0160","unstructured":"EudraCT Number 2008-003235-20 - NOPHO-ALL-2008 treatment protocol for children (1.0 - 17.9 years of age) with acute lymphoblastic leukemia. EU Clinical Trials Register. www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-003235-20\/SE [accessed January 4, 2022]."},{"key":"10.1016\/j.drudis.2022.01.002_b0165","unstructured":"EudraCT Number 2016-001935-12 - AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia. EU Clinical Trials Register. https: \/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-001935-12\/DE [accessed January 4, 2022]."},{"issue":"3","key":"10.1016\/j.drudis.2022.01.002_b0170","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clml.2015.12.004","article-title":"A Phase II Study of Coltuximab ravtansine (SAR3419) monotherapy in patients with relapsed or refractory acute lymphoblastic leukemia","volume":"16","author":"Kantarjian","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.drudis.2022.01.002_b0175","unstructured":"The European Parliament and the Council of Europe. Regulation (EU) No 536\/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001\/20\/EC. OJ. 2014; L158: 1\u201376."},{"issue":"2","key":"10.1016\/j.drudis.2022.01.002_b0180","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejca.2013.09.027","article-title":"Complying with the European Clinical Trials directive while surviving the administrative pressure - an alternative approach to toxicity registration in a cancer trial","volume":"50","author":"Frandsen","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.drudis.2022.01.002_b0185","unstructured":"NCT03643276 - International Collaborative Treatment Protocol for Children and Adolescents with Acute Lymphoblastic Leukemia - AIEOP\u2013BFM ALL 2017. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03643276 [accessed January 4, 2022]."},{"key":"10.1016\/j.drudis.2022.01.002_b0190","unstructured":"NCT01802814 \u2013 International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 A randomized Phase III study conducted by the Resistant Disease Committee of the International BFM Study Group. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01802814 [accessed January 4, 2022]."},{"key":"10.1016\/j.drudis.2022.01.002_b0195","unstructured":"NCT01802814 - A phase III randomized trial for newly diagnosed high risk B-lymphoblastic leukemia (B-ALL) including a stratum evaluating dasatinib (NSC#732517) in patients with Ph\u2013like tyrosine kinase inhibitor (TKI) sensitive mutations. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02883049 [accessed January 4, 2022]."},{"key":"10.1016\/j.drudis.2022.01.002_b0200","unstructured":"NCT03911128 - A treatment study protocol of the ALLTogether Consortium for children and young adults (1\u201345 Years of Age) with newly diagnosed acute lymphoblastic leukaemia (ALL): a pilot study. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03911128 [accessed January 4, 2022]."},{"key":"10.1016\/j.drudis.2022.01.002_b0205","unstructured":"NCT03117751 \u2013 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03117751 [accessed January 4, 2022]."},{"issue":"4","key":"10.1016\/j.drudis.2022.01.002_b0210","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000279","article-title":"Chimeric antigen receptor T-cell therapy clinical results in pediatric and young adult B-ALL","volume":"3","author":"DiNofia","year":"2019","journal-title":"Hemasphere"},{"key":"10.1016\/j.drudis.2022.01.002_b0215","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Assessment report Kymriah - EMA\/485563\/2018. European Medicines Agency. www.ema.europa.eu\/en\/documents\/assessment-report\/kymriah-epar-public-assessment-report_en.pdf [accessed January 4, 2022]."},{"issue":"2","key":"10.1016\/j.drudis.2022.01.002_b0220","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1634\/theoncologist.2019-0233","article-title":"The European Medicines Agency review of Kymriah (tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma","volume":"25","author":"Ali","year":"2020","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.drudis.2022.01.002_b0225","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28112","article-title":"Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia","volume":"67","author":"Shah","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.drudis.2022.01.002_b0230","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000496870","article-title":"Chimeric antigen receptor T cells: a race to revolutionize cancer therapy","volume":"46","author":"Subklewe","year":"2019","journal-title":"Transfus Med Hemother"},{"issue":"2","key":"10.1016\/j.drudis.2022.01.002_b0235","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000188","article-title":"CAR-T cells: future perspectives","volume":"3","author":"Charrot","year":"2019","journal-title":"Hemasphere"},{"issue":"4","key":"10.1016\/j.drudis.2022.01.002_b0240","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150089","article-title":"Antibody-drug conjugates as novel anti-cancer chemotherapeutics","volume":"35","author":"Peters","year":"2015","journal-title":"Biosci Rep"},{"issue":"3","key":"10.1016\/j.drudis.2022.01.002_b0245","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.drudis.2022.01.002_b0250","first-page":"119","article-title":"Comparison of total body irradiation before and after chemotherapy in pretreatment for hematopoietic stem cell transplantation","volume":"27","author":"Li","year":"2012","journal-title":"Cancer Biother Radiopharm"},{"issue":"2","key":"10.1016\/j.drudis.2022.01.002_b0255","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.bmt.1705963","article-title":"Searching for alternative hematopoietic stem cell donors for pediatric patients","volume":"41","author":"Rocha","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.drudis.2022.01.002_b0260","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3389\/fped.2019.00295","article-title":"Hematopoietic stem cell transplantation in primary immunodeficiency diseases: current status and future perspectives","volume":"7","author":"Castagnoli","year":"2019","journal-title":"Front Pediatr"},{"issue":"6","key":"10.1016\/j.drudis.2022.01.002_b0265","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/bjh.13896","article-title":"Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence","volume":"172","author":"Bleckmann","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.drudis.2022.01.002_b0270","doi-asserted-by":"crossref","first-page":"29559","DOI":"10.1038\/srep29559","article-title":"Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib","volume":"6","author":"Dessilly","year":"2016","journal-title":"Sci Rep"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622000022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622000022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:56:04Z","timestamp":1761224164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644622000022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1359644622000022"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2022.01.002","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The changing landscape of treatment options in childhood acute lymphoblastic leukaemia","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2022.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}